Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014348 | 0.87 | CA2 (0.32) | CA2 | |
| SCHEMBL22014416 | 0.85 | NLRP3 (0.42) | NLRP3CA2 | |
| SCHEMBL25067006 | 0.81 | NLRP3 (0.44) | NLRP3CA2 | |
| SCHEMBL22014419 | 0.81 | NLRP3 (0.30) | NLRP3 | |
| SCHEMBL20698839 | 0.81 | NLRP3 (0.41) | NLRP3 | |
| SCHEMBL22014583 | 0.79 | NLRP3 (0.42) | NLRP3CA2 | |
| SCHEMBL20698687 | 0.79 | NLRP3 (0.42) | NLRP3CA2 | |
| SCHEMBL20698686 | 0.79 | NLRP3 (0.42) | NLRP3CA2 | |
| SCHEMBL20698948 | 0.79 | NLRP3 (0.45) | NLRP3CA2 | |
| SCHEMBL25067039 | 0.78 | NLRP3 (0.40) | NLRP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885CA2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.